Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn about a paper by Benjamin Garmezy et al. published in Oncogene:

“A remarkable work, Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor

Invariant natural killer T (iNKT) cells, previously considered to be tissue-resident, are an emerging and versatile allogeneic cell therapy with potent anti-tumor activity, acting at the interplay between innate and adaptive immune responses.

We report an unprecedented complete remission in a heavily pre-treated metastatic germ cell neoplasm, using ex vivo expanded allogeneic iNKT cells, warranting further trials.”

Title: Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor

Authors: Benjamin Garmezy, Joseph E. Grossman, Jennifer Buell, Thiago Favano, Justin Stebbing, Steven O’Day, Marco A. Purbhoo, Dhan Chand, F. Anthony Greco

You can read the Full Article in Oncogene.

Hung Trinh: iNKT Cells at the Interplay Between Innate and Adaptive Immune Responses